INTRODUCTION {#s1}
============

Diabetes prevalence has increased globally from 4.7% in 1980 to 8.5% in 2014 among adults over 18 years of age \[[@R1]\]. Diabetes can damage blood vessels, eyes, and kidneys, resulting in microvascular complications \[[@R1]--[@R3]\], and is a contributing factor in 2.6% of global blindness cases \[[@R1], [@R4]\].

Erythropoietin (EPO) is a kidney-derived peptide hormone that plays a major role in the stimulation of bone marrow stem cells and erythropoiesis \[[@R5]--[@R7]\]. EPO can promote retinal angiogenesis independently of VEGF in proliferative diabetic retinopathy \[[@R8], [@R9]\]. In diabetic retinas, EPO protects retinal cells by upregulating ZnT8 via ERK pathway activation and HIF-1α expression inhibition \[[@R10]\], and EPO may slow progression of diabetic nephropathy (DN) \[[@R11], [@R12]\]. EPO can also improve cardiac function by suppressing endoplasmic reticulum stress and inducing SERCA2a expression \[[@R13]\].

Several studies have examined associations between EPO polymorphisms and diabetic complications; however, the results have been inconsistent. Fan, *et al.* suggested that erythropoietin polymorphisms increased diabetic retinopathy risk \[[@R14]\]. Conversely, Balasubbu, *et al.* found no significant association \[[@R15]\]. Thus, our study investigated relationships between single-nucleotide polymorphisms (SNPs) in the EPO gene and diabetic complications.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Figure [1](#F1){ref-type="fig"} shows our study selection process. In total, 688 studies were retrieved from the PubMed, Embase, Cochrane library, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases. Of these, 151 duplicates were excluded from this study. Another 493 studies were excluded after reviewing the titles and abstracts. 44 eligible studies were evaluated for full-text review. Of these, 35 were excluded due to non-reporting of available data, duplicate data, or because they were meta-analyses and case reports. Nine original articles containing 12 studies remained after full-text review (Tables [1](#T1){ref-type="table"}--[2](#T2){ref-type="table"}) \[[@R14]--[@R22]\].

![Study selection flow chart](oncotarget-08-112675-g001){#F1}

###### Main characteristics of studies included in the meta-analysis, by EPO SNP

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP                            Diabetic microvascular complications   Author                        Year      Region              Type of diabetes mellitus   Genotyping method   Case   Control   Case   Control   HWE   Quality                                                  
  ------------------------------ -------------------------------------- ----------------------------- --------- ------------------- --------------------------- ------------------- ------ --------- ------ --------- ----- --------- ----- ----- ------ ----- ------- ------ ------ ---
                                                                                                                                                                                                     TT     TG        GG    T         G     TT    TG     GG    T       G             

  rs1617640                      Diabetic retinopathy                   Abhary, *et al.* (1) (T1DM)   2010      Australia           T1DM                        Sequencing          106    67        40     44        18    124       80    24    30     11    78      52     0.76   6

  Abhary, *et al.* (2) (T2DM)    2010                                   Australia                     T2DM      Sequencing          179                         166                 65     78        27     208       132   64        88    11    216    110   0.01    6             

  Balasubbu, *et al.*            2010                                   Indian                        T2DM      Taqman assay        345                         359                 32     163       150    227       463   30        171   158   231    487   0.08    6             

  Yang, *et al.*                 2014                                   China                         T2DM      Sequencing          216                         284                 146    55        10     347       75    182       82    16    446    114   0.11    7             

  Zhang                          2014                                   China                         T2DM      PCR-LDR             448                         344                 293    138       13     724       164   225       98    15    548    128   0.31    6             

  Gong                           2015                                   China                         T2DM      Mass spectrometry   128                         128                 77     40        11     194       62    92        36    0     220    36    0.06    6             

  Li, et al.                     2016                                   China                         T2DM      PCR                 191                         130                 58     121       71     237       263   27        51    9     105    69    0.04    7             

  Fan, et al.                    2016                                   China                         T2DM      Taqman assay        397                         796                 208    161       28     577       217   468       302   26    1238   354   0.01    6             

  Diabetic retinopathy\          Tong, *et al.* (1)                     2008                          America   T2DM                SNaPshot                    374                 239    150       172    52        472   276       66    127   46     259   219     0.28   7      
  and end- stage renal disease                                                                                                                                                                                                                                                       

  Tong, *et al.* (2)             2008                                   America                       T1DM      SNaPshot            865                         574                 335    419       111    1089      641   148       307   119   603    545   0.08    7             

  Tong, *et al.* (3)             2008                                   America                       T1DM      SNaPshot            379                         141                 139    180       60     458       300   35        78    28    148    134   0.20    7             

                                 Diabetic nephropathy                   Alwohhaib, *et al.*           2014      Kuwait              T2DM                        Taqman assay        76     128       NA     NA        NA    73        3     NA    NA     NA    118     10     NA     4

                                                                                                                                                                                                     TT     TC        CC    T         C     TT    TC     CC    T       C             

  rs507392                       Diabetic retinopathy                   Abhary, *et al.* (1) (T1DM)   2010      Australia           T1DM                        Sequencing          106    67        40     44        18    124       80    24    30     11    78      52     0.76   6

  Abhary, *et al.* (2) (T2DM)    2010                                   Australia                     T2DM      Sequencing          179                         166                 65     78        27     208       132   63        88    11    214    110   0.01    6             

  Zhang                          2014                                   China                         T2DM      PCR-LDR             448                         344                 281    149       14     711       177   225       98    24    548    146   0.01    6             

  Fan, et al.                    2016                                   China                         T2DM      Taqman assay        397                         796                 202    161       34     565       229   463       305   28    1231   361   0.01    6             

                                                                                                                                                                                                     AA     AC        CC    A         C     AA    AC     CC    A       C             

  rs551238                       Diabetic retinopathy                   Abhary, *et al.* (1) (T1DM)   2010      Australia           T1DM                        Sequencing          106    67        40     44        18    124       80    24    30     11    78      52     0.76   6

  Abhary, *et al.* (2) (T2DM)    2010                                   Australia                     T2DM      Sequencing          179                         166                 65     78        27     208       132   64        88    11    216    110   0.01    6             

  Zhang                          2014                                   China                         T2DM      PCR-LDR             448                         344                 286    140       13     712       166   219       92    24    530    140   0.002   6             

  Yang, *et al.*                 2014                                   China                         T2DM      Sequencing          216                         284                 141    65        10     347       85    182       79    17    443    113   0.04    7             

  Gong                           2015                                   China                         T2DM      Mass spectrometry   128                         128                 76     40        12     192       64    90        36    2     216    40    0.45    6             

  Fan, et al.                    2016                                   China                         T2DM      Taqman assay        397                         796                 203    156       38     562       232   452       299   45    1203   389   0.63    6             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SNP, single-nucleotide polymorphism; PCR-LDR, polymerase chain reaction-ligation detection reaction; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; NA, not available; HWE, Hardy-Weinberg equilibrium

###### Main characteristics of studies included in the meta-analysis, by individual study

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                Abhary (2010)                 Balasubbu (2010)           Yang (2014)                     Zhang (2014)                     Gong (2015)                      Li (2016)                        Fan (2016)                   Tong (2008)              Alwohhaib (2014)
  ------------------------ ----------------------------- -------------------------- ------------------------------- -------------------------------- -------------------------------- -------------------------------- ---------------------------- ------------------------ ------------------
  Mean age (SD)\           T1DM (*P* \< 0.001)\          57(9) vs. 59(11)\          50.67(9.41) vs. 52.7(7.61)\     62.35(11.92) vs. 60.16(11.67)\   62.19(8.26) vs. 67.17(9.95)\     63.10(6.83) vs. 68.48(6.91)\     56.1(14.2) vs. 56.9(14.1)\   68 vs. 70\               NA
  Case vs. Control         48.6(16.0) Vs. 36.3(14.6)\    *P* = 0.37                 *P* = 0.008                     *P* = 0.13                       *P* = 0.019                      *P* \< 0.001                     *P* = 0.357                  67 vs. 44\               
                           T2DM(*P* = 0.82)\                                                                                                                                                                                                        40 vs. 52                
                           64.2(11.1) vs. 64.5(15.1)                                                                                                                                                                                                                         

  Males(%), mean(SD)\      T1DM (*P* = 0.87)\            242 (70) vs. 208 (58)\     103 (48) vs.111 (39)\           196 (44) vs. 163 (47)\           61 (48) vs. 58 (45)\             98 (51) vs.73 (56)\              187 (47.1) vs. 392 (49.2)\   232 (62) vs. 150 (63)\   NA
  Case vs. Control         54(51) vs.35(52)\             *P* = 0.05                 *P* = 0.054                     *P* = 0.31                       *P* = 0.707                      *P* = 0.517                      *P* = 0.534                  437 (51) vs. 247 (49)\   
                           T2DM (*P* \< 0.001)\                                                                                                                                                                                                     230 (40) vs. 191 (50)    
                           114 (63) vs. 73 (44)                                                                                                                                                                                                                              

  Duration of DM\          T1DM (*P* \< 0.001)\          14 (9) Vs. 14 (9)\         13.44 (7.22) vs.14.79 (4.97)\   13.61 (7.31) vs. 10.70 (7.01)\   14.27 (6.70) vs. 8.07 (5.44)\    15.74 (7.48) vs. 17.74 (7.10)\   9.5 (3.8) vs. 5.7 (3.0)\     22 vs. 19\               NA
  (years)\                 28.1 (11.7) vs.12.43 (8.1)\   *P* = 0.42                 *P* = 0.013                     *P* = 0.001                      *P* \< 0.001                     *P* \< 0.001                     *P* \< 0.001                 49 vs. 32\               
  mean (SD)\               T2DM (*P* \< 0.001)\                                                                                                                                                                                                     25 vs. 35                
  Case vs. Control         17.3 (8.4) vs. 12.6 (8.9)                                                                                                                                                                                                                         

  Smoker (%), mean (SD)\   T1DM (*P* = 0.93)\            NA                         NA                              NA                               NA                               NA                               148 (37.3) vs. 273 (34.2)\   NA                       NA
  Case vs. Control         54 (51) vs. 34 (51)\                                                                                                                                                                        *P* = 0.321                                           
                           T2DM (*P* = 0.52)\                                                                                                                                                                                                                                
                           99 (55) vs. 86 (52)                                                                                                                                                                                                                               

  HbA1c level, %\          T1DM (*P* = 0.07)\            6.4 (1.6) vs. 6.4 (1.2)\   7.84 (1.70) vs.6.97 (1.40)\     9.31 (2.88) vs. 8.57 (2.03)\     8.06 (1.54) vs. 7.74 (1.91)\     7.45 (0.49) vs. 6.84 (0.85)\     NA                           8 vs. 7.6\               NA
  mean (SD)\               9.2 (7.5) vs. 7.5 (2.0)\      *P* = 0.09                 *P* \< 0.001                    *P* = 0.07                       *P* = 0.426                      *P* \< 0.001                                                  10.9 vs. 7.8\            
  Case vs. Control         T2DM (*P* = 0.005)\                                                                                                                                                                                                      7.4 vs. 8.1              
                           8.5 (8.6) vs. 6.5 (3.1)                                                                                                                                                                                                                           

  BMI, mean (SD)\          T1DM (*P* = 0.73)\            NA                         25.8 (4.13) vs. 25.26 (3.95)\   25.58 (4.18) vs. 26.16 (4.75)\   23.84 (2.71) vs. 23.71 (2.82)\   NA                               23.4 (6.7) vs. 25.3 (6.2)\   NA                       NA
  Case vs. Control         25.4 (10.1) vs. 25.9 (6.7)\                              *P* = 0.14                      *P* = 0.30                       *P* = 0.842                                                       *P* \< 0.001                                          
                           T2DM (*P* = 0.01)\                                                                                                                                                                                                                                
                           29.7 (10.9) vs. 32.5 (9.1)                                                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA, not available; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; SD, standard deviation.

Hardy-Weinberg equilibrium (HWE) was assessed via Chi-square test in the control subjects of each study. Genotype distributions among controls were consistent with HWE in only eight studies \[[@R15]--[@R20]\]. These eight studies, which investigated three SNPs (rs1617640, rs507392 and rs551238), were included in the final meta-analysis. The eight studies included 2,861 cases and 2,136 controls. Five studies focused on diabetic retinopathy, and three focused on diabetic retinopathy and end-stage renal disease. Four examined patients with type 2 diabetes mellitus (T2DM), and one examined patients with type 1 diabetes mellitus (T1DM). Four included patients of Asian descent, three included patients of American descent, and one included patients of Australian descent. According to the Newcastle-Ottawa quality assessment scale (NOS), quality scores ranged from 6--7, and the median score of the case-control studies was 6.5.

EPO rs1617640 quantitative analyses {#s2_2}
-----------------------------------

Eight studies investigated the association between EPO rs1617640 gene polymorphisms and diabetic complications risk \[[@R15]--[@R20]\]. Differences were observed in the genotype model (TT vs. GG: OR = 1.544, 95% CI = 1.089--2.189, *P* = 0.015) (Figure [2](#F2){ref-type="fig"}, Table [3](#T3){ref-type="table"}). For diabetic retinopathy, rs1617640 polymorphisms were not associated with increased complication risk in any genetic model (allele model: OR = 0.960, 95% CI = 0.769--1.198, *P* = 0.717; genotype model: TG vs. GG: OR = 0.975, 95% CI = 0.756--1.259, *P* = 0.847, TT vs. GG: OR = 1.003, 95% CI = 0.714--1.410, *P* = 0.985; dominant model: OR = 0.988, 95% CI = 0.774--1.261, *P* = 0.923; recessive model: OR = 0.990, 95% CI = 0.820--1.196, *P* = 0.921) (Figure [3](#F3){ref-type="fig"}). In T2DM and Asian populations, no association was observed in any genetic model (allele model: OR = 0.940, 95% CI = 0.721--1.227, *P* = 0.651; genotype model: TG vs. GG: OR = 0.983, 95% CI = 0.753--1.283, *P* = 0.898, TT vs. GG: OR = 1.075, 95% CI = 0.552--2.093, *P* = 0.832; dominant model: OR = 1.057, 95% CI = 0.601--1.859, *P* = 0.846; recessive model: OR = 0.980, 95% CI = 0.804--1.195, *P* = 0.844). For diabetic retinopathy and end-stage renal disease, rs1617640 polymorphisms were associated with diabetic microvascular complications in all genetic models (allele model: OR = 1.486, 95% CI = 1.324--1.667, *P* = 0.000; genotype model: TG vs. GG: OR = 1.317, 95% CI = 1.052--1.648, *P* = 0.016, TT vs. GG: OR = 2.209, 95% CI = 1.730--2.821, *P* = 0.000; dominant model: OR = 1.607, 95% CI = 1.298--1.990, *P* = 0.000; recessive model: OR = 1.792, 95% CI = 1.502--2.138, *P* = 0.000). Only one study assessed T1DM in Australian populations, and no association was found in any genetic model (allele model: OR = 1.033, 95% CI = 0.659--1.620, *P* = 0.886; genotype model: TG vs. GG: OR = 0.896, 95% CI = 0.371--2.165, *P* = 0.808, TT vs. GG: OR = 1.019, 95% CI = 0.412--2.517, *P* = 0.968; dominant model: OR = 0.951, 95% CI = 0.417--2.168, *P* = 0.904; recessive model: OR = 1.102, 95% CI = 0.580--2.094, *P* = 0.766).

![Forest plots of the association between rs1617640 polymorphisms and diabetic microvascular complication susceptibility. (TT vs. GG)\
Squares and horizontal lines correspond to the study-specific OR and 95% CI. The diamond represents the summary OR and 95% CI.](oncotarget-08-112675-g002){#F2}

###### ORs and 95% CIs for EPO gene polymorphisms and diabetic microvascular complications using different genetic models

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP         Comparison     Subgroup     N   Heterogeneity test   Z test\   Publication bias   OR and 95% CI                                  
                                                                   P~Z~                                                                        
  ----------- -------------- ------------ --- -------------------- --------- ------------------ --------------- ------- ---------------------- ----------------------
  rs1617640   T vs. G        Overall      8   0.000                76.4      0.180              0.174           0.037   1.251 (1.146, 1.365)   1.142 (0.940, 1.387)

                             DR           5   0.049                58.1      0.717              0.221           0.356   0.991 (0.867, 1.134)   0.960 (0.769, 1.198)

                             T2DM         4   0.023                68.5      0.651                                      0.987 (0.857, 1.137)   0.940 (0.721, 1.227)

                             T1DM         1                                  0.886                                      1.033 (0.659, 1.620)   1.033 (0.659, 1.620)

                             Asian        4   0.023                68.5      0.651                                      0.987 (0.857, 1.137)   0.940 (0.721, 1.227)

                             Australian   1                                  0.886                                      1.033 (0.659, 1.620)   1.033 (0.659, 1.620)

                             DR+DN        3   0.780                0         0.000                                      1.486 (1.324, 1.667)   1.485 (1.324, 1.667)

              TG vs. GG      Overall      8   0.246                23.0      0.095              0.174           0.163   1.154 (0.975, 1.366)   1.169 (0.944, 1.447)

                             DR           5   0.202                32.9      0.847              0.221           0.462   0.975 (0.756, 1.259)   1.028 (0.679, 1.555)

                             T2DM         4   0.118                48.9      0.898                                      0.983 (0.753, 1.283)   1.040 (0.597, 1.810)

                             T1DM         1                                  0.808                                      0.896 (0.371, 2.165)   0.896 (0.371, 2.165)

                             Asian        4   0.118                48.9      0.898                                      0.983 (0.753, 1.283)   1.040 (0.597, 1.810)

                             Australian   1                                  0.808                                      0.896 (0.371, 2.165)   0.896 (0.371, 2.165)

                             DR+DN        3   0.544                0         0.016                                      1.317 (1.052, 1.648)   1.317 (1.051, 1.649)

              TT vs. GG      Overall      8   0.022                57.2      0.015              0.019           0.002   1.677 (1.377, 2.043)   1.544 (1.089, 2.189)

                             DR           5   0.147                41.2      0.985              0.221           0.092   1.003 (0.714, 1.410)   1.098 (0.663, 1.820)

                             T2DM         4   0.078                56.0      0.832                                      1.001 (0.693, 1.444)   1.075 (0.552, 2.093)

                             T1DM         1                                  0.968                                      1.019 (0.412, 2.517)   1.019 (0.412, 2.517)

                             Asian        4   0.078                56.0      0.832                                      1.001 (0.693, 1.444)   1.075 (0.552, 2.093)

                             Australian   1                                  0.968                                      1.019 (0.412, 2.517)   1.019 (0.412, 2.517)

                             DR+DN        3   0.665                0         0.000                                      2.209 (1.730, 2.821)   2.208 (1.729, 2.820)

              TT+TG vs. GG   Overall      8   0.050                50.3      0.059              0.063           0.185   1.296 (1.104, 1.522)   1.294 (0.991, 1.691)

                             DR           5   0.162                38.9      0.923              0.462           0.463   0.988 (0.774, 1.261)   1.054 (0.692, 1.606)

                             T2DM         4   0.090                53.9      0.846                                      0.992 (0.768, 1.280)   1.057 (0.601, 1.859)

                             T1DM         1                                  0.904                                      0.951 (0.417, 2.168)   0.951 (0.417, 2.168)

                             Asian        4   0.090                53.9      0.846                                      0.992 (0.768, 1.280)   1.057 (0.601, 1.859)

                             Australian   1                                  0.904                                      0.951 (0.417, 2.168)   0.951 (0.417, 2.168)

                             DR+DN        3   0.538                0         0.000                                      1.607 (1.298, 1.990)   1.607 (1.297, 1.991)

              TT vs. TG+GG   Overall      8   0.001                72.2      0.087              0.019           0.002   1.365 (1.201, 1.551)   1.257 (0.968, 1.632)

                             DR           5   0.274                22.1      0.921              0.221           0.092   0.990 (0.820, 1.196)   0.986 (0.789, 1.233)

                             T2DM         4   0.170                40.2      0.844                                      0.980 (0.804, 1.195)   0.968 (0.740, 1.266)

                             T1DM         1                                  0.766                                      1.102 (0.580, 2.094)   1.102 (0.580, 2.094)

                             Asian        4   0.170                40.2      0.844                                      0.980 (0.804, 1.195)   0.968 (0.740, 1.266)

                             Australian   1                                  0.766                                      1.102 (0.580, 2.094)   1.102 (0.580, 2.094)

                             DR+DN        3   0.981                0         0.000                                      1.792 (1.502, 2.138)   1.792 (1.502, 2.138)

  rs507392    T vs. C        Overall      1                                  0.886                                      1.033 (0.659, 1.620)   1.033 (0.659, 1.620)

              TC vs. CC      Overall      1                                  0.808                                      0.896 (0.371, 2.165)   0.896 (0.371, 2.165)

              TT vs. CC      Overall      1                                  0.968                                      1.019 (0.412, 2.517)   1.019 (0.412, 2.517)

              TT+TC vs. CC   Overall      1                                  0.904                                      0.951 (0.417, 2.168)   0.951 (0.417, 2.168)

              TT vs. TC+CC   Overall      1                                  0.766                                      1.102 (0.580, 2.094)   1.102 (0.580, 2.094)

  rs551238    A vs. C        Overall      3   0.151                47.1      0.002                                      0.774 (0.658, 0.911)   0.769 (0.585, 1.012)

              AC vs. CC      Overall      3   0.225                33.0      0.011                                      0.598 (0.402, 0.890)   0.596 (0.331, 1.073)

              AA vs. CC      Overall      3   0.086                59.2      0.104                                      0.529 (0.358, 0.782)   0.515 (0.231, 1.147)

              AA+AC vs. CC   Overall      3   0.112                54.3      0.003                                      0.561 (0.385, 0.817)   0.546 (0.268, 1.111)

              AA vs. AC+CC   Overall      3   0.384                0         0.026                                      0.791 (0.643, 0.973)   0.791 (0.643, 0.973)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P*~H~: P-value of heterogeneity test; *P*~Z~: P-value of Z test; *P*~B~: P-value of Begg\'s test; *P*~E~: P-value of Egger\'s test; OR: odds ratio; 95% CI: 95% confidence interval; N: number of comparisons

![Forest plots of the association between rs1617640 polymorphisms and diabetic retinopathy susceptibility (TT vs. GG)\
Squares and horizontal lines correspond to the study-specific OR and 95% CI. The diamond represents the summary OR and 95% CI.](oncotarget-08-112675-g003){#F3}

EPO rs507392 quantitative analyses {#s2_3}
----------------------------------

Only one study investigated the relationship between EPO rs507392 polymorphisms and diabetic retinopathy \[[@R16]\]. No association was observed in any genetic model (allele model: OR = 1.033, 95% CI = 0.659--1.620, *P* = 0.886; genotype model: TC vs. CC: OR = 0.896, 95% CI = 0.371--2.165, *P* = 0.808, TT vs. CC: OR = 1.019, 95% CI = 0.412--2.517, *P* = 0.968; dominant model: OR = 0.951, 95% CI = 0.417--2.168, *P* = 0.904; recessive model: OR = 1.102, 95% CI = 0.580--2.094, *P* = 0.766.

EPO rs551238 quantitative analyses {#s2_4}
----------------------------------

Three studies were eligible for the EPO rs551238 meta-analysis \[[@R14], [@R16], [@R20]\]. An association was found between EPO rs551238 polymorphisms and diabetic retinopathy (allele model: OR = 0.774, 95% CI = 0.658--0.911, *P* = 0.002; genotype model: AC vs. CC: OR = 0.598, 95% CI = 0.402--0.890, *P* = 0.011; dominant model: OR = 0.561, 95% CI = 0.385--0.817, *P* = 0.003; recessive model: OR = 0.791, 95% CI = 0.643--0.973, *P* = 0.026) (Figure [4](#F4){ref-type="fig"}).

![Forest plots of the association between rs551238 polymorphisms and diabetic retinopathy susceptibility (A vs\
C). Squares and horizontal lines correspond to the study-specific OR and 95% CI. The diamond represents the summary OR and 95% CI.](oncotarget-08-112675-g004){#F4}

Publication bias and sensitivity analysis {#s2_5}
-----------------------------------------

Begg\'s funnel plot and Egger\'s test were employed to detect publication bias in this meta-analysis. We found no evidence of publication bias, with the exception of rs1617640 (TT vs. GG, TT vs. TG+GG), which exhibited a slight publication bias (Figure [5](#F5){ref-type="fig"}, Table [3](#T3){ref-type="table"}). A sensitivity analysis was performed to examine the influence of excluding each study on the pooled ORs. The overall effects were not altered when each study was omitted, suggesting that our meta-analysis results were reliable (Figure [6](#F6){ref-type="fig"}).

![Publication bias tested by Begg\'s funnel plot (rs1617640 T vs\
G). Each point represents a separate study for the indicated association. Logor, natural logarithm of OR. Horizontal line, mean effect size.](oncotarget-08-112675-g005){#F5}

![Sensitivity analysis of each study performed by omitting each data set from the analysis (rs1617640 TT vs\
GG).](oncotarget-08-112675-g006){#F6}

DISCUSSION {#s3}
==========

EPO is located on chromosome 7q21 and encodes a potent angiogenic factor expressed in the retina and kidney \[[@R23]--[@R25]\]. Several studies have assessed the impacts of EPO single-nucleotide polymorphisms (SNPs) on diabetic microvascular complications; however, the results have been inconsistent. We performed this meta-analysis to obtain conclusive results regarding the relationship between EPO polymorphisms and diabetic microvascular complications. We evaluated the most commonly investigated EPO polymorphisms: rs1617640, rs507392, and rs551238. Our results indicate that EPO polymorphisms are a risk factor for diabetic microvascular complications.

We searched several databases for relevant studies assessing the association between the EPO polymorphisms and diabetic complications. Our analysis included eight studies with a combined total of 2,861 cases and 2,136 controls. These studies were conducted between 2008 and 2015 to investigate the association between EPO polymorphisms and diabetic retinopathy and nephropathy. Tong, *et al.* suggested an association between the T allele of SNP rs1617640 and proliferative diabetic retinopathy as well as end-stage renal disease \[[@R19]\]. Gong associated higher diabetic retinopathy risk with carrying the TT/GT genotype and T allele at the EPO gene site rs1617640 \[[@R20]\]. Abhary, *et al.* concluded that all three EPO SNPs (rs507392, rs1617640, and rs551238) were associated with diabetic retinopathy risk independent of duration of DM, degree of glycemic control, and nephropathy \[[@R16]\]. However, some studies found no associations \[[@R15]\]. In our study, the pooled results indicated a relationship between rs1617640 polymorphisms and diabetic complications (genotype model: TT vs. GG: OR = 1.544, 95% CI = 1.089--2.189, *P* = 0.015).

Our subgroup study stratified by complication type showed that rs1617640 polymorphisms were associated with diabetic retinopathy and end-stage renal disease. However, the association with diabetic retinopathy was not significant in any model. Only one study evaluated T1DM in Australian populations, so we were not able to evaluate statistical significance in this case.

Only one study investigated rs507392 polymorphisms, and found no association between these polymorphisms and diabetic retinopathy. Three studies investigated the association between EPO rs551238 polymorphisms and diabetic retinopathy risk, with inconsistent results. We pooled the results and found a relationship between rs551238 polymorphisms and diabetic retinopathy.

Our meta-analysis had some limitations. First, the number of included studies was relatively small. rs1617640 polymorphisms were examined in eight studies, and rs507392 and rs551238 polymorphisms were investigated in one and three studies, respectively. Previous studies demonstrated that EPO variations played roles in DR and DN development \[[@R19], [@R26]\], and different results were found for T2DM and T1DM. Thus, we performed a subgroup study stratified by complication type, DM type, and ethnicity. However, some of our stratified analyses were limited by small sample sizes. Three studies focused on DR and DN. Only one study assessed T1DM in an Australian population. There were some differences between cases and controls, including patient age, gender, duration of DM, HbA1c level and BMI (Table [2](#T2){ref-type="table"}). Stratification analyses based on differences in DM duration, gender, or other factors could not be performed because of limited sample sizes. Data from large, multi-center studies, including DM severity, ethnicity, and other complications and factors, are needed to confirm these relationships. Second, due to the limited number of studies, we did not investigate publication bias for the rs551238 polymorphism. A small publication bias was detected for the rs1617640 polymorphism in some models (TT vs. GG, TT vs. TG + GG), indicating that some unpublished studies might have been overlooked. Third, heterogeneity was found between the rs1617640 polymorphism studies; however, we could not conduct subgroup analyses to investigate the heterogeneity source due to the limited number of studies. Finally, we did not examine other risk factors, such as environmental effects and genetic factors.

In summary, we found that EPO polymorphisms are a risk factor for diabetic microvascular complications. rs1617640 polymorphisms are associated with increased risk of diabetic retinopathy and nephropathy, and rs551238 polymorphisms are associated with increased risk of diabetic retinopathy.

MATERIALS AND METHODS {#s4}
=====================

Search for eligible studies {#s4_1}
---------------------------

Relevant studies were retrieved from the PubMed, Embase, Cochrane library, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases. The last search was performed on August 22, 2017, with keywords including ("erythropoietin" OR "erythropoietin-generating factor" OR "renal erythropoietic factor" OR "erythropoitin-generating factor" OR "EPO" OR "rs1617640" OR "rs507392" OR "rs551238") AND ("gene" OR "Polymorphisms, Genetic" OR "Polymorphisms, Genetic" OR "Genetic Polymorphism" OR "Polymorphism (Genetics)" OR "Genetic Polymorphisms" OR "Polymorphism" OR "genetic" OR "allele" OR "variation" OR "variant" OR "mutation") AND ("Diabetes" OR "Diabetes-Related " OR "Diabetic ") AND ("Complication" OR "Complications" OR "Disease, Retinal" OR" Diseases, Retinal " OR "Retinal Disease" OR "retinopathy" OR "nephropathy" OR " Disease, Kidney" OR " Kidney Disease" OR "vascular" OR "Blood Vessel" OR "Vessel, Blood" OR "Vessels, Blood" OR "Neuropathy" OR "Neuropathies" OR "Neuralgia" OR "Neuralgias" OR "Cardiomyopathy" OR "Myocardial Diseases" OR "Disease, Myocardial" OR "Diseases, Myocardial" OR "Myocardial Disease" OR "Myocardiopathies" OR "Myocardiopathy"). We also manually searched the reference lists of relevant reports to identify additional studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

All selected studies in this analysis met the following criteria: (1) case-control studies; (2) explored the correlation between EPO polymorphisms and diabetic microvascular complications; and (3) contained sufficient data for calculating odds ratios (ORs) and 95% confidence intervals (95% CIs). Exclusion criteria were as follows: (1) studies without Hardy-Weinberg equilibrium (HWE) in the control groups; (2) studies not relevant to diabetic complications or lacking a control population; and (3) studies lacking sufficient data for quantitative analyses.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators (Li H and Xu HP) independently reviewed all articles and extracted available data from individual studies. Any discrepancies were resolved by discussion between these two investigators. The following information was extracted from each eligible study: (1) first author, (2) year of publication, (3) country of origin and ethnicity of study participants, (5) type of diabetes mellitus and complications, (6) genotyping method, (7) number of cases and controls, (8) polymorphism and genotype distribution, and HWE for controls. We assessed the quality of each eligible study according to the Newcastle-Ottawa quality assessment scale (NOS) \[[@R27]\]. Quality score ranged from 0--9.

Statistical analysis {#s4_4}
--------------------

HWE was assessed via Chi-square test in the control populations of each study. Pooled ORs and corresponding 95% CIs were calculated to estimate associations between EPO polymorphisms and diabetic microvascular complications. Z test was used to assess the overall effect and *P* \< 0.05 was considered statistically significant. The strength of the association was determined using the following models: allele model (T vs. G, T vs. C, A vs. C), genotype model (TG vs. GG, TT vs. GG, TC vs. CC, TT vs. CC, AC vs. CC, AA vs. CC), dominant model (TT/TG vs. GG, TT/TC vs. CC, AA/AC vs. CC), and recessive model (TT vs. TG/GG, TT vs. TC/CC, AA vs. AC/CC). Subgroup analyses were conducted according to ethnicity, type of diabetes mellitus, and complication. We used the *Q*-statistic and I^2^ statistic to evaluate statistical heterogeneity among studies \[[@R27]\]. *P* ≥ 0.1 and I^2^ \< 50% suggested a lack of heterogeneity among studies. A random-effect model was used through the DerSimonian and Laird method in the presence of heterogeneity (*P* \< 0.1 or I^2^ \> 50%); otherwise, a fixed-effect model based on the Mantel-Haenszel method was employed (*P* ≥ 0.1 or I^2^ \< 50%). We conducted a sensitivity analysis to assess the stability of the results. Egger\'s test and Begg\'s funnel plot were used to evaluate publication bias. Analyses were performed using STATA version 11.0 software (Stata Corporation, College Station, TX, USA).
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